Cadila Healthcare gains on receiving tentative approval from USFDA for Clofarabine Injection

10 Mar 2016 Evaluate

Cadila Healthcare is currently trading at Rs. 346.10, up by 2.00 points or 0.58% from its previous closing of Rs. 344.10 on the BSE.

The scrip opened at Rs. 348.00 and has touched a high and low of Rs. 348.95 and Rs. 342.80 respectively. So far 44,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 454.40 on 23-Oct-2015 and a 52 week low of Rs. 295.50 on 18-Jan-2016.

Last one week high and low of the scrip stood at Rs. 348.95 and Rs. 331.05 respectively. The current market cap of the company is Rs. 35,431.73 crore.

The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 14.35% and 10.86% respectively.

Cadila Healthcare has received tentative approval from the USFDA to market Clofarabine Injection 20mg/20ml vials. The group now has more than 100 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in FY 2003 - 04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.


Zydus Lifesciences Share Price

881.10 13.30 (1.53%)
19-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1166.45
Cipla 1391.20
Zydus Lifesciences 881.10
Lupin 2178.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×